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                                                      ABBREVIATIONS 
 
 
AALSD    : American Association for Study of Liver disease 
AFP         : alpha feto protein 
ALT          :  Alanine Transaminase 
Anti HBc : Antibody to Hepatitis C Core antigen 
Anti Hbs : antibody to Hepatitis B surface antigen 
AST         : Aspartate Transaminase 
cccDNA : Covalently closed circular DNA 
CHB        : Chronic Hepatitis B 
DNA       : Deoxyribo Nucleic Acid 
HBeAg   : Hepatitis B e antigen 
HbsAg   : Hepatitis B surface antigen 
HBV      : Hepatitis B Virus 
HCC      : Hepatocellular Carcinoma 
HCV      : Hepatitis C Virus 
HIV       : Human immunodeficiency virus 
INR       : International Normalized Ratio 
MELD   : Model for End Stage disease  
NS         : Not significant 
NUC’s   : Nucleotide analogues 
ORF        :  Open Reading Frames 
Peg-IFN : pegylated Interferon 
qHBsAg :  quantification of Hepatitis B surface antigen 
RNA       : Ribo Nucleic Acid 
ROC       : Receiver Operating characteristics  
RT          : Reverse transcriptase 
SVR       : Sustained Virological response 
ULN       : Upper limit of normal 
USG       : Ultrasonography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 ABSTRACT 
 
Aim: To study the correlation of   HBsAg quantification  levels with HBV DNA  
in patients with chronic hepatitis B infection.Also to study the role of  qHbsAg 
levels in predicting the response to antiviral therapy in  chronic hepatitis B 
infection. 
Materials and methods : one year prospective study conducted between January 
2014-2015 at department of digestive health and diseases, kilpauk medical 
college,chennai. All patients of chronic hepatitis B infection were included in the 
study. Baseline liverfunction tests, HbsAg quantification and HBVDNA levels 
were done. In treatment group the above values are repeated every 12 weeks for 36 
weeks. 
 Results :  Total of 160 patients were included and among them 24 were in 
treatment group. The results are as follows. In the treatment naïve group,  serum 
HBsAg  levels are higher in HBeAg  positive group than HBeAg negative group 
with a mean of 4.25logIU/ml and 2.81logIU/ml respectively . so qHBsAg levels  
had  significant correlation with  HBVDNA levels in HBeAg  positive group ( P  
<0.001) but not in HBeAg negative group. Serum qHBsAg  levels  also 
differentiates  immune-tolerant from immune-clearance phase with mean  values of  
4.59logIU/ml  and 3.74logIU/ml respectively(P=0.038).We observed that  Serum 
HbsAg levels are higher in active chronic hepatitis B group than inactive carriers 
with a values of 4.20logIU/ml and 2.64logIU/ml respectively ( P=0.002). From the 
above ROC curve,  serum HBsAg level of 3.01logIU/ml  indicates high chances of 
replicative state with 96% sensitivity and 76% specificty. In treatment with NUC‘s 
we observed decline in serum qHbsAg  levels are slow and less pronounced that 
HBVDNA in both HBeAg positive &HBeAg negative group. 
conclusion: High serum qHBsAg levels has a good correlation with HBV DNA 
levels in HBeAg positive than HBeAg negative patients. Single point estimation of 
qHBsAg levels can predict replicative state and can act as a surrogate marker for 
the replicative state. Higher qHBsAg levels also differentiates inactive CHB from 
active CHB and can replace  HBV DNA levels in differentiatin the two. Estimation 
of qHBsAg is easy and cost effective. Serum qHBsAg levels decline slowly  with 
NUC‘s  than DNA levels and  decrease in serum qHBsAg levels  does not correlate 
with  decrease in HBV DNA levels.  
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                                               INTRODUCTION  
 
                                       Hepatitis B infection is a major  health problem 
affecting  approximately  about 350 million globally. Annually about   
600,000 people die  from hepatitis B-associated liver disease 
1
 . 
Approximately 0.8–1.4 million individuals are chronically infected with 
HBV in the United states alone 
2
.  Since the discovery of  surface antigen , 
HBsAg  remained as the gold standard for the diagnosis of HBV infection
3
. 
Though the vital role  of HBsAg quantification was discovered long ago, its 
usefulness was not studied or observed. The reason may be due to lack of 
simple test and it‘s availability unlike recent days. Hence  estimation of 
qHBsAg levels use was restricted in clinical practice .  The knowledge 
behind the usefulness of HBsAg quantification based on that there is strong 
and positive  association with covalently closed circular (ccc) DNA which is 
the template for viral replication in the hepatocytes 
4
. 
                                          
                                   
                      Serum HBsAg levels comprises of virions and non-infectious  
HBsAg particles(filaments &spherical) . During the course of the disease,  
Filaments decrease and goes in parallel with virions where as the  spherical 
particles remain stable and  in moderate excess in low viraemic  HBeAg 
negative carriers. Thus, HBsAg production varies both quantitatively and 
qualitatively over time and  during different phases of the infection
5
.  Serum 
HBsAg  levels starts declining gradually  from the immune-tolerant (IT)  to 
immune clearance(IC) phase with higher values in immunotolerant phase 
and lower levels in immune clearance phase. There is no clear cut-off values 
in each phases as various studies showed different values.  In immune-
tolerant patients, the median values showed variability i.e  5 logIU/ml from  
European study , 4.9 logIU/ml  from Hong Kong study and  only 4.5 
logIU/ml  from Asia study 
7
.   
                                                 Also there is wide fluctuations in DNA levels 
and ALT levels in IT & IC phase which makes it difficult to differentiates IT 
from IC phase ,but  serum HBsAg levels can   differentiate  IT from IC 
phase  by  higher qHBsAg  levels in IT phase than IC phase , the mean 
serum HBsAg level was 4.96 log IU/ml vs. 4.37 log IU/ml,  in IT and IC 
phase respectively 
6
.  And the rate of decline in qHBsAg levels varies at 
each phases of HBV life cycle. Studies have shown  that decline in HBsAg 
is less pronounced in HBeAg-negative patients than in HBeAg-positive 
patients .   HBsAg  quantification levels also helps in monitoring the 
treatment response  and guides in stopping the therapy. Studies have shown 
that qHBsAg  levels of more 1 logIU/ml decline at 12 weeks from base line 
had sensitivity  of 78% , specificity of 96% in predicting the sustained 
response.  so HBsAg levels can guide in stopping of antiviral therapy in  
CHB
8
. So , this study is done to evaluate the role of  HBsAg quantification 
in treatment naïve  chronic hepatitis B infection and also in predicting the 
treatment response. 
 
 
 
 
 
 
 
 
 
 
 
                               OBJECTIVES OF THE STUDY 
 
1. Correlation of  HBsAg quantification  levels with HBV DNA levels in 
patients with chronic hepatitis B infection. 
 
2. Role of hepatitis B surface antigen quantification in predicting the response 
to antiviral therapy in  chronic hepatitis B infection. 
 
 
 
 
 
 
 
 
 
                                        REVIEW OF LITERATURE 
 
 
                                               Hepatitis B surface antigen (HBsAg) was discovered  
by Blumberg in 1965, and since then HBsAg has been used as the goldstandard  
for the diagnosis of  hepatitis B  infection
1
. Worldwide over 2 billion people are 
infected with HBV, among those 400 million are chronically infected. Chronic 
hepatitis B infection can progress to complications like cirrhosis,  decompensation  
of  liver and hepatocellular carcinoma. Although most of them will not develop 
these complications, only 15- 40% will develop complications  over a period of 
many years
9
.  
 
HEPATITIS B VIRUS: 
                                        The hepatitis B virus is a DNA virus belongs to the 
hepadnaviridae family. Hepatits B virion is also known as  the Dane particle which 
is 42-nm. It contains small DNA genome inside nucleocapsid which is surrounded 
by an outer envelope called surface antigen(HBsAg) 
10
. 
 
  
 
Epidemiology and Prevalence : 
  
                                     The prevalence of  Hepatitis B  infection varies  widely and  
globally due  to differences in the predominant mode of transmission and the age at 
infection. The regions are divided based on rate of prevalences.  In highly 
prevalence regions like Southeast Asia (excluding Japan) and sub Saharan Africa,  
the commonest mode of infection is by perinatal transmission  accounting for 40-
60 % of chronic B infection(CHB). In the  intermediate  prevalent countries India, 
Japan, the Middle East and some parts of southern and eastern Europe, CHB 
accounts for 20% with a carrier rate of 3-5%. Horizontal mode of transmission is 
the most common mode in these regions. Countries  like  Australia, North 
America, western Europe,  and some regions  of South America has a low 
prevalence with carrier rate of 0.1-  2%. The major modes of transmission in these 
regions are sexual transmission and injection drug users .
[11-13]
 
                                       The  significant impact on the clinical outcome depends on 
the age at infection occurs. The rate of  chronic infection  is  90% in infants 
infected at birth,  25–50% if infected between  1 and 5 years, and  < 5% if infected 
during adult life 
[14-17]
. 
 
 
 
Molecular biology of  Hepatitis B virus: 
 Molecular biology:  
                                         
                                       The  genome  of  Hepatitis B virus has four important  
open reading frames (ORFs). HBV genome  has a compact design with a several 
genes on it. These genes overlap with each other  and  they encode different viral 
proteins by using the same DNA molecule . The genes which encode the open 
reading frames  are the core, surface, X, and polymerase genes.  
                                         The largest gene among these four is Polymerase gene 
with approximately 800 amino acids and this gene overlaps with the entire length 
of the surface ORF. This polymerase gene Codes for DNA polymerase/reverse 
transcriptase and the function of this gene includes packing and DNA 
replication((includes RNA- and DNA-dependent DNA polymerase,  RNase H 
activities and priming ) . The surface gene ‗S‘ codes for the small surface protein 
called HBsAg. The preceding pre-S1 and pre-S2 proteins in ORF-S along with S 
protein codes for small[S], medium [M] and large[L] proteins. These proteins 
functions as viral recognition by hepatocyte receptors.   
 
                                              Among these small, medium and large proteins are 
expressed  on the surface of Dane particle. Where as the small surface protein is 
expressed in subviral particles. The core gene ‗C‘ codes  for the  hepattis B core 
nucleo-capsid protein (HBcAg), which is important in viral packaging and 
production of HBeAg. The X gene encodes the HBx protein, which has a potent  
transcriptional  and transactivating properties and may be important in hepatic 
carcinogenesis. 
                                    
                                         The hepatitis B virus  replication occurs through an RNA 
intermediate  with the  help of active viral reverse transcriptase/polymerase 
enzyme.  Hepatitis B virus has higher mutation rate than  any  other DNA viruses 
(an estimated 10
10
 to 10
11
 point mutations per day).
18
  HBV genomic sequencing 
has identified a large number of mutations within the  genome,  of which many  are 
silent or does not alter the amino acid sequence of encoded proteins. In view of  of 
genomic overlap, some of the silent mutations in one ORF  may result in an amino 
acid substitution in an another overlapping ORF ( for example , from polymerase 
gene to surface gene),which may be the cause for variability in response to 
treatment, but clinical implications are uncertain as the data is lacking on this
19
. 
                           
                 
                 
                       
figure 1:open reading frames(ORF‘s) of genome with major transcripts (wavy lines) 
 
 
 
  
 THE LIFE CYCLE OF HBV:  
                                                
                                                  The life cycle begins with the attachment of  the 
virus to the hepatocyte  but the receptor for  the virus attachment to the hepatocyte 
has not been identified.  The initial phase is attachment of virion to host cell and 
enters inside by fusion of viral & host membranes. After entering the virus into the 
hepatocyte,  it  undergoes uncoating, and then Hepatitis B virus  genome enters the 
nucleus. Following which repairing of the single-stranded DNA strand and 
formation of the covalently closed circular (ccc) DNA template occurs. Then the  
Viral transcripts are formed for the hepatitis B surface antigen (HBsAg), DNA 
polymerase, X protein, and RNA pregenome. The RNA  pregenome and  DNA 
polymerase are  incorporated into the maturing nucleocapsid and removed after 
translation.  
                                              The surface protein enveloping process occurs in the 
endoplasmic reticulum. Some of the nonenveloped nucleocapsid re-circulates back 
to the nucleus, and the cycle begins again. Excess tubular and spherical forms of 
HBsAg are secreted in great abundance. 
                                       S protein is synthesized in the endoplasmic reticulum, 
where monomer aggregates that exclude host membrane proteins subsequently bud 
into the lumen as subviral particles. When formed, HBsAg undergoes 
glycosylation in the endoplasmic reticulum and the Golgi apparatus. Noninfectious 
subviral particles (spherical and filamentous forms of HBsAg) are secreted in great 
abundance when compared with mature virions 
19
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: life cycle of Hepatitis B virus 
 
 
 Hepatitis B Virus Genotypes20: 
                        
                                       There  are 8 genotypes identified so far from A to H 
based on their nucleotide sequence, distributed all over the world with wide 
variation. The significance  in identifying these genotypes are due to varied 
response to therapy( mainly interferon)  and plays a vital role in determining 
the disease activity and risk of progression of the disease.  In India the 
predominant genotype is ‗D‘, where as the other part of Asian countries 
genotype ‗B‘ and genotype ‗C‘ are predominant.  
 
 HBV serotypes : 
                                HBV serotypes are classified based on antigenic 
determinant on the small S protein.  The common determinant is ‗a‘ and 
additionally  there are two pairs of mutually exclusive allelic antigens i.e ‗y‘ 
versus ‗d‘ and ‗w‘ versus ‗r‘. Thus, there are 4 possible major serotypes 
includes, ayw, ayr, adw, adr.  
                                   The details of the genotypic distribution and their 
clinical association with the disease process are described in the  following 
table . 
 
 
 
Table 1: 
Geographic Distributions 
    A: Northwestern Europe, North America, Central Africa 
   
 B: Southeast Asia, including China, Japan, and Taiwan (prevalence is 
       increasing in North America) 
    C: Southeast Asia (prevalence is increasing in North America) 
    D: Southern Europe, Middle East, India 
    E: West Africa 
    F: Central and South America, United States (Native Americans), Polynesia 
    G: United States of America, France 
    H: Central and South America 
 
 
 
 
 
 
 
 
 
 Continuation of table 1: 
Proposed Clinical Associations 
    Time to HBeAg seroconversion and probability of HBsAg loss: B < C 
    Response to  interferon-α: A > B ≥ C > D 
   
 Precore/core promoter mutant frequency: precore mutation not selected with 
A and F 
    Liver disease activity and risk of progression: B < C 
    Evolution to chronic liver disease: A < D 
   
 Hepatocellular carcinoma risk: B > C in younger age group in Taiwan but   
B < C in older age group in Japan 
 
 
 
 
 
 
 
 
 
HEPATITIS B SURFACE ANTIGEN KINETICS : 
 
                                             HBsAg is the glycosylated envelope protein of the 
mature HBV virion. Three HBsAg proteins exists namely small (S), medium 
(M),and large (L) proteins. Apart from virions ,serum HBsAg levels derives  
mainly from non-infectious HBsAg particles (20 nm diameter filaments ) which 
does not contain viral nucleic acids and exceed virions by a factor ranging from 
10
2
-10
5
. 
21  
HBsAg derives mainly from the intrahepatic viral minichromosome 
(cccDNA) by translation of specific RNAs that are distinct from pregenomic 
RNAHBV replication occurs via the pregenomic RNA (pgRNA),a separate RNA 
transcript, therefore  the HBsAg secretory follows a distinct pathway from viral 
replication pathway distinct processes within the hepatocyte
22
. 
 
                                        The ratios between defective HBsAg particles and virions 
are not stable, but change over time. Filaments and spherical particles are produced 
in large excess in highly viraemic hepatitis B ‗e‘ antigen (HBeAg)-positive 
carriers. While filaments decline in parallel with virions, spherical particles remain 
in moderate excess in low viraemic  HBeAg negative carriers.  
Thus HBsAg production varies both quantitatively and qualitatively over time  and  
appears to be dynamically regulated during different phases of the infection
23,24
. 
From the  diagnostic perspective, it is important to appreciate that HBsAg 
quantification detects all three forms of circulating HBsAg.  
 
                                    The antibodies used in the quantitative enzyme 
immunoassays target epitopes in the S protein.  Therefore not capable of 
distinguishing  between virion-associated HBsAg, subviral particles and HBsAg 
produced from integrated sequence
24
. Currently, there are two commercialized 
assay that can measure the HBsAg quantification, the Architect QT assay  and the 
Elecsys HBsAg II Quant assay 
25
. 
 
 
 Natural history of surface antigen(HBsAg): 
 
                                             Studies have shown that HBsAg production varies 
both quantitatively and qualitatively over time and  during different phases.  Their  
decline in their  levels  also varies   progressively from the immune-tolerant  to 
immune clearance phase. Various  studies have reported  that ,higher and more 
stable HBsAg levels in HBeAg-positive immune-tolerant carriers, with values  
 
about half a log higher than  immune clearance phase . HBsAg titers can correlate 
with serum HBV DNA and intrahepatic cccDNA levels, but  vary in  different 
phases of disease
26
 .  
                                           There is a strong  correlation between HBsAg , cccDNA 
and  serum DNA levels  in  HBeAg-positive patients, where as in  HBeAg-negative 
patients DNA & cccDNA levels  are  reduced relatively  but   HBsAg titers have 
been  preserved relative to other two. The  exact is reason  is not known , but  
postulated theory says that there  is preferential control of the replicative pathway 
over HBsAg transcription or secretion, where virion production is inhibited but 
secretion of subviral particles is preserved
27,28
. To determine the utility of  HBsAg 
measurement in HBeAg-negative patients studies are needed. 
                                      The following  diagram shows the comparisons of serum 
HbsAg  levels, HBV DNA and serum ALT levels during different phase of  
treatment naïve  chronic hepatitis B infection ( figure 3).  
 
   
                      
 
          
          Figure 3: HBsAg, DNA & ALT levels in different phases 
 
 
 
 
HBsAg kinetics in various stages: 
  HBeAg-positive chronic hepatitis B: 
 
                                                In peri-natally acquired infection, HBeAg crosses 
placenta and induces immune tolerance. This phase usually occurs after 10-20 
years of life which is characterized by  HBeAg positive,normal  transminases, very 
high HBV DNA, and minimal histologic damage. Following which is the immune 
clearance phase which may leads to HBeAg seroconversion
29
. 
 
                                              HBsAg levels vary in both immune tolerance and 
clearance phase but does not fluctuates unlike DNA & ALT levels. Studies have 
shown that  the serum HBsAg levels were  higher  and steady  in the immune 
tolerance phase than in the immune clearance phase . Also observed HBsAg levels 
were persistently high in HBeAg in immune tolerance phase
26,27
.  An European 
study compared HBsAg levels in immune tolerance & immune clearance phase 
which showed the mean serum HBsAg level was 4.96 log IU/ml vs. 4.37 log IU/ 
ml, in immune tolerance and immune clearance phase respectively 
27
.  
                                               Same study showed that very high HBsAg 
levels(100,000 IU/ml ) can be supportive of immune tolerance phase. But there is 
no consensus guidelines regarding the particular cut-off to differentiate between 
the two phases.  
 
 HBeAg-negative chronic hepatitis B: 
 
                                              The prevalence of HBeAg-negative CHB is  
increasing worldwide  and it is important to recognize because recognizing and 
treating will prevent the damage to the liver.  This group is classified as ―inactive 
carrier state‖ and ―chronic hepatitis state‖.  Since there is  wide fluctuation of 
serum HBV DNA levels and biochemical activity between the these two states it is 
difficult to diagnosis with a single determinant value and need serial measurements 
of ALT and HBV DNA levels
30-33
. 
 
                                          Both the American and European guidelines recommend 
HBV DNA cut-off of 2000IU/ml to differentiate inactive carriers from chronic 
hepatitis
34,35
. But this cut-off is controversial as most of the countries are not 
accepting
36-38
.  
                                         Quantification of HBsAg levels were studied in these 
groups to make it precise,definitive and supportive. Based on several longitudinal 
studies, they found that serum HBsAg levels are higher among active HBeAg-
negative CHB  group than in inactive carriers. One study states  that the mean 
serum HBsAg level was 3.81 log IU/ml in active CHB and  in the inactive carrier 
state it is2.25 log IU/ml (P<0.05)after following for 11 years
39
.  
 
                                      Another study states that serum HBsAg levels were 
significantly low in inactive (56) than in active CHB (153 ) with the  median 
values of 62.12 (0.1–4068) IU/ml vs. 3029 (0.5–82,480) IU/ml, respectively (p 
<0.001)
40,41
. The exact cut-off is lacking to differentiate between the two groups. 
Same study said that the combination of HBsAg <1000 IU/ml and HBV DNA 
<2000 IU/ml rather than single variable  allowed identifying inactive carriers from 
active CHB with a PPV 87.9% and NPV 96.7%
41
.  Needs more studies to validate 
the particular cut –off in identifying the inactive carriers. 
 
 
 
 
 
 
 
HBsAg kinetics with treatment response: 
 
 Variation with Peg-interferon treatment 
 
 HBeAg-positive patients: 
 
                                            Initial studies showed dramatic decrease in  serum 
HBsAg level with interferon therapy among HBeAg positive patients and they also 
had sustained response (HBeAg seroconversion and HBV DNA <2000 IU/ml)  
5 years post treatment . Early serological response at 12weeks ( defined as low 
HBsAg level or greater HBsAg decline) is associated with higher rates of 
seroconversion and DNA suppression rates 6 months post treatment
42-44
.  
 
 
The following table shows various studies supporting the above evidence (table 2).   
 
 
 
 
 
Table 2:  percentage of HBeAg-positive patients with sustained virological response (SVR) 
as predicted by serum HBsAg at week 12 and 24 of treatment 
 
 
Author  HBsAg 
decline 
Prediction at12week  
% patient      %SVR 
Prediction at 24 wk 
%patient        %SVR 
Ref
. 
Sonneveild et 
al 
No decline 31                   3 25                      8 47 
Piratvisuth et al No decline 24                   18  NA                   NA 48 
Lau et al <1500IUml 23                   57 34                     54 44 
Gane et al. <1500IU/ml 27                   58 40                     57 46 
Chan et al. <300IU/ml 
and >1og 
decline 
 NA                NA 13                     75 45 
 
 
          
                                              
                                                  
                                                 These studies showed that  decline in serum HBsAg 
level at week 12 and week 24 with peg-interferon can be used as a surrogate 
marker to predict sustained virological response in  HBeAg-positive CHB. Also 
identifies the group of patients who do not respond to treatment, hence stopping 
rule can be applied to those non-responders. Most of the studies recommend that, 
absence of the decline in serum HBsAg level of >2000IU/ml at week12 stopping 
rule can be considered in those groups 
47,48
. To recommend the above cut-off needs 
more studies and validation. 
 
 
 HBeAg-negative patients:  
 
                                         HBeAg negative patients achieve undetectable DNA 
levels to interferon therapy but relapse post stopping. Hence monitoring HbsAg 
levels in those patients may add better surrogate marker for attaining sustained 
response. Decline in HBsAg levels do occur in HBeAg negative patients like 
HBeAg positive bit the response rates are comparatively low.  Rijckborst V et al 
study states failure to decline in>2 log HBsAg and   > 2log  DNA levels did not 
respond or achieve sustained response, hence stopping rule can be considered
49
.  
                                     
                                             The validation of   this possible stopping rule was 
confirmed in the recent study done  in  cohorts of HBeAg-negative genotype D 
patients treated for either 1 or 2 years with peg-interferon alfa-2a
50
.  
 
 
 Variation with  nucleos(t)ide analogues: 
 
                                       Following  nucleoside therapy the decline in serum 
HBsAg levels are slow and less pronounced  and does not parallel with DNA 
levels unlike with  interferon therapy. Studies have shown that average time to 
HBsAg loss with NA treatment is >10years compared to DNA which is 5 years
51
. 
The reason for slow decline in HBsAg levels is nucleosides inhibit only the 
cytoplasmic pregenomic RNA but does not target the  intranuclear  cccDNA. On 
the other hand  interferons  acts by both immune mediated and antiviral effects
52
. It 
is also found that  serum HBsAg levels persists even after elimination of DNA 
levels, with a slow progressive decline eventually
54
.   
 
 
 
 
  HBeAg-positive patients 
  
                                      Though the rate of decline is slow with NAs compare to 
interferon, rate of decline is comparatively rapid among HBeAg positive patients 
compare to HBeAg negative. A study in China conducted using 11 patients. They 
found that  HBsAg decline of  > 1 log  was predictive of HBsAg. Also observed 
HBsAg levels <100IU/ml at the end of treatment predicted a sustained response for 
2 years post stopping the drug
53
.  
 
 
 HBeAg-negative patients 
 
                                           HBsAg  decline is less pronounced in HBeAg-negative 
patients than in HBeAg-positive .The validation of predicting the treatment 
response and the stopping rule is controversial in this group. Some studies showed 
positive impact and some had negative impact. A study done at Honkong showed 
patients with  HBsAg decline of  > 1log at 12 months could predict a sustained 
viral response than the patients who haad < 1 log decline in HBsAg levels 
55
.  
                                         However a German  study showed early decline in 
HBsAg at 12 months did not had a sustained response
52
. In Asian study which 
included genotype B and C patients, they concluded that an HBsAg level of 
<100IU/ml with NUC‘s might predict lower risk of relapse and stopping can be 
considered
53,5,56
.  
 
                                      But to recommend the cut-off for stopping the drug , 
multicentre  RCT‘s are needed. Overall, decline in serum HBsAg  is slow and does 
not go in parallel with HBV DNA levels during treatment with NUC‘s. However, a 
rapid decline in serum HBsAg levels, ( after virological response ) may identify 
patients who will clear HBsAg in the long-term. 
 
 
 
 
 
 
 
 
 
    CLINICAL MANIFESTATIONS :  
 
Clinical manifestations depends upon age at infection occurs, host immunity and 
level of replication of virus. Infection occurring during childhood or peri-natally is 
asymptomatic but has high risk for chronicity where as adulthood infection will be 
usually symptomatic with low risk of chronicity. 
 
                    Hepatitis B infection has a wide spectrum of manifestations in both 
acute and chronic phase. 
 
1. Acute phase :  
 Subclinical hepatitis 
 Anicteric hepatitis 
 Icteric hepatitis 
 Acute liver failure 
 
2. Chronic phase: 
 Inactive carrier state 
  Active Chronic hepatitis 
  Compensated cirrhosis of liver 
 Decompensated cirrhosis of liver 
 Hepatocellular carcinoma 
 
3. Extrahepatic manifestations :  
 Arthritis  
 Dermatitis  
 Glomerulonephritis  
 Polyarteritis nodosa 
 Cryoglubulinemia 
 Polymyalgia rheumatica 
 Popular acrodermatitis(Gianotti-Crosti disease) 
 Serum sickness 
 
 
 
 
 
 
 
 
  
Definitions used in hepatitis B infection:  
 
 Chronic hepatitis B: 
                            1. HBsAg-positive  6 months 
                            2. Serum HBV DNA  20,000 IU/mL (10
5
copies/mL),lower values 
                                    2,000- 20,000 IU/ml (10
4
-  10
5
 copies/mL) are   often seen in  
                                    HBeAg-negative chronic hepatitis B.  
                            3. Persistent or intermittent elevation in ALT/AST levels 
                           4. Liver biopsy showing chronic hepatitis with moderate or  
                              severe  necro-inflammation . 
 
 Inactive HBsAg carrier state : 
                            1. HBsAg-positive 6 months 
                            2. HBeAg –ve, anti-Hbe + ve 
                            3. Serum HBV DNA  < 2,000 IU/mL 
                            4. Persistently normal ALT/AST levels 
                            5. Liver biopsy confirms absence of significant hepatitis 
 
 Resolved hepatitis B: 
1. Previous known history of acute or chronic hepatitis B or the  
 presence of anti-HBc  ± anti-HBs  
                            2. HBsAg  negative  
                            3. Undetectable serum HBV DNA* 
                            4. Normal ALT levels. 
 
 Acute exacerbation or flare of hepatitis B : 
                                Defined as intermittent elevations  of  aminotransferase 
activity to more than 10 times the  upper limit of normal and more than 
twice the baseline value in an inactive chronic hepatitis B infection. 
 
 HBeAg clearance: 
                             Defined as the loss of  serum HBeAg in a person who was 
previously HBeAg positive. 
 
 
 
 
 
 HBeAg seroconversion : 
                               Defined as the loss of HBeAg and detection of anti-HBe 
in a person who was previously HBeAg positive and anti-HBe negative. 
 
 HBeAg reversion: 
                                 Reappearance of HBeAg in a person who was 
previously  HBeAg negative, anti-HBe positive. 
 
 HBsAg seroconversion :  
                              Defined as the loss of serum surface antigen(HBsAg) 
with appearance of anti-Hbs in the serum. 
 
 
 
 
 
 
 
 
 
  
Outcome of chronic infection:  
 
 
                  Figure 4 : course of CHB infection 
  
 
 
Factors Associated with Progression of HBV-related Liver Disease 
 
 Increased rates of cirrhosis    
 
a) Host and viral risk factors  
1. Older age (longer duration of infection),  
2. HBV genotype C,  
3. High levels of HBV DNA, 
4. Habitual alcohol consumption, and  
5. Co-  infection with HCV(10- 15%) HDV or HIV (6-13%) 
 
b) Enivonmental Factors 
1)  heavy alcohol consumption, 
2) carcinogens such as aflatoxin, and, 
3) smoking 
 
 
 
 
 
 Increased rates of HCC   
 
a) Host and viral risk factors 
1)  Male gender, 
2) Family history of HCC,  
3) Older age, 
4) History of reversions from anti-HBe to HBeAg,  
5) Presence of cirrhosis, 
6) HBV genotype C, 
7) Core promoter mutation, and 
8) Coinfection with HCV. 
 
b) Enivonmental Factors  
1)  heavy alcohol consumption, 
2) carcinogens such as aflatoxin, and, 
3) smoking 
 
 
 
 
 EVALUATION OF PATIENTS WITH CHRONIC HBV INFECTION: 
 
   1. History and physical examination 
   2. Family History of liver disease, HCC 
             3. Laboratory tests to assess liver disease 
                                  i.  Complete blood counts  with platelets 
                       ii.  Liver function test, 
                       iii.  Prothrombin time  
                       iv. Renal function test 
    4. Tests for HBV replication :  HBeAg/anti-HBe, HBV DNA(RT- PCR)  
    5. Tests to rule out viral co-infections:  anti-HCV and anti-HIV  in those 
at risk 
    6. Tests to screen for HCC–AFP  and ultrasound liver at baseline and 
every 6months  in high risk patients. 
    7. Consider liver biopsy to grade and stage liver disease 
                             - for patients who meet criteria for chronic hepatitis 
 
 
 
APPROVED THERAPY: 
 
                       Currently, seven therapeutic agents have been approved for 
the treatment of adults with chronic hepatitis B in the United States. The use 
of  interferons in the management of CHB is restricted  with the  wide 
availability nucleotide analogues. The duration of treatment varies with the 
type of therapy and stage of the disease. The interferons are used only for 52 
weeks and their response also varies with the type of genotype, where as 
nucleoside analogues duration is not fixed unlike interferons.  Duration of 
therapy with nucleotides varies with the stage of disease.  
 
 Interferon (IFN) — conventional and pegylated.  
 
 Five nucleos(t)ide analogues  under three groups.  
             L –nucleosides        – Lamivudine and Telbivudine;  
             Acyclic nucleoside            – Adefovir dipivoxil  
                                                           Tenofovir disoproxil fumarate; and 
            Deoxyguanosine analogues – Entecavir  
 
       
  Table  3 :   
Drugs Advantages  Disadvantages  
Interferons  
• Finite therapy 
• Durable off treatment 
response 
• 5 -8% of HbsAg loss 
 
• Iv injections 
• Side effects 
• Expensive 
• Low response rate in 
pts with high viremia 
Nucleosides 
• Negligible side effects 
• Potent inhibition of 
viral replication. 
• Less expensive  
 
• Drug resistance 
• Therapy duration? 
• Lowest rate of HbsAg 
disappearance 
 
 
 
 
 
 
  Factors to Consider in Initiating  anti-HBV Therapy 
                               The factors to be considered before initiating the therapy 
are based on the following 
 
i. HBV DNA levels                     
ii. ALT levels                                
iii. HBeAg status 
iv.  Cirrhosis  vs no cirrhoisis 
v. Compensated cirrhosis  vs decompensated 
vi. Others  
- Pregnancy state to prevent vertical transmission 
- Prior to chemotherapy 
- HIV positive state 
 
 
 
 
 
 
Treatment recommendations :  
 Table 4 : AASLD recommendations 
 
 
 
 
TREATMENT END POINTS: 
 
 Interferon regimes : 
 HBeAg-positive chronic hepatitis B  
                                 -16 weeks for standard IFN  
                                 -48 weeks for pegIFN-. (I) 
 
 HBeAg-negative chronic hepatitis B  
                                   - 48 weeks for both standard and pegIFN- (II-3)  
 
 
 Duration of nucleoside analogue treatment:  
 
 HBeAg-positive chronic hepatitis B: 
 
                                      - Treatment should be continued until the patient has 
achieved HBeAg seroconversion and undetectable serum HBV DNA and 
completed at least 6 months of additional treatment after appearance of 
 anti-HBe. (I) 
                                   -  Close monitoring for relapse is needed after 
withdrawal of treatment.  
 
 HBeAg-negative chronic hepatitis B : 
- Treatment should be continued until the patient has 
achieved HBsAg clearance. (I)  
 
 
 Compensated cirrhosis :  
                        Ideally long-term treatment is advised.  
 
a) HBeAg-positive patients  
                         Till  confirmed HBeAg seroconversion and have completed  at 
least 6 months of consolidation therapy. 
 
 
b) HBeAg-negative patients  
          Till confirmed HBsAg clearance. (II-3) 
         - Close monitoring for viral relapse and hepatitis flare is mandatory if 
treatment is stopped. (II-3). 
   Decompensated cirrhosis and recurrent hepatitis B post–liver 
transplantation:  
                            Life-long treatment is recommended. (II-3)  
 
 
 
 
 
 
 
 
 
 
             
 
 
                              
                     MATERIALS AND METHODS 
 
                                              The study population included all  the patients  of 
chronic hepatitis B fulfilling the inclusion criteria who attended  Department of 
Digestive Health and Diseases, Government Peripheral Hospital, Anna Nagar, 
Chennai-600 102. 
 
                                     The period of study is from January 2014 to January 
2015.  Patients were included in the study after obtaining their willingness to 
undergo necessary investigations.  Informed written consent was obtained from the 
study participants before enrollment.   
  
Ethical Committee approval was obtained for performing the study.   
 
 
 
 
 
 
 
  
Inclusion criteria : 
1. Chronic hepatitis B infection 
2. HBV related compensated cirrhosis of liver 
3. HBV related decompensated cirrhosis of liver  
 
Exclusion criteria :  
 
1. Acute hepatitis B 
2. Co infection with HCV 
3. Co infection with HIV 
 
 
 
 
 
 
 
 
 
                                           Methodology 
 
                                          All the patients satisfying the inclusion and exclusion 
criteria were enrolled in to the study.    
Follow up :   
                Liver function tests,  HBsAg quantification and HBV-DNA levels  were 
done for every 12 weeks for 1 year . 
 The diagnosis of chronic hepatitis B is made on the basis of duration of  
HBsAg status(HbsAg positive for more than 6 months). 
 The diagnosis of chronic liver disease is made on the basis of evidence of 
portal hypertension and cirrhosis in ultrasonography and presence of varices 
in  upper gastrointestinal endoscopy. 
 
 
 
 
 
 
 
Clinical evaluation: 
 
  Detailed history regarding present and past history of jaundice, 
ascites, gastrointestinal bleeding, pedal edema, hepatic encephalopathy, 
blood transfusion, surgeries, extra marital sexual exposure, alcohol intake, 
associated  co-morbidities, etc. were noted.   
   
  Clinical examination was  done to check for the evidence of chronic 
liver disease such as jaundice, spider angioma, dupuytrens contracture, 
palmar erythema, gynaecomastia, ascites, splenomegaly, caputmedusae, 
asterixis. 
 
Laboratory investigations: 
 Blood investigations like hemoglobin, WBC count, platelet count, 
prothrombin time, INR,  S.bilirubin,  T.protein, albumin, alanine aminotransferase, 
aspartate aminotransferases, HBSAg, Anti HCV, HIV,  urea, creatinine, USG 
abdomen, Gastroscopy, liver biopsy if necessary.  Child  Turcotte Pugh score and 
MELD score were calculated using the various parameters.   
 
         Baseline measurements: HBsAg quantification, HBV DNA levels. 
  
 
Treatment :  
                  Those who fulfilled the criteria for treatment recommendation 
were started on the available drugs 
- Tenofovir 
- Lamivudine( Children) 
 
 
 
 
 
 
 
 
                                              STATISTICS:    
                 
                                           Statistical analyses of these data was done using 
Receiver operating curve and Pearson co-efficient equation . 
 Any statistical difference was considered significant at P< 0.05.  
           p.value 0.000 to 0.010 is highly significant. 
  p.value 0.011 to 0.050 is significant. 
  p.value 0.051 to 1.000 is not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
                                             
                                                     RESULTS 
Total of 160 patients were included in my study, of which 26 are in the treatment 
group. The results are as follows 
                                 FLOW CHART OF THE STUDY: 
      Figure 5 :  
ITT: Intention to treat                      
Total patients 
160 
No treatment
n=134
Treatment group
n=26
2 discontinued
ITT
N=24
 
Sex distribution :  
 
   
       Table 5: sex distribution 
sex Male Female  Total  
No .s 86(53.75%) 74(46.25%) 160 
 
        Figure 5: pie chart showing sex distribution 
                                
In our study we found that males are more than  females but  there is no significant 
sex predilection. This may be explained by the predominant route of transmission 
(vertical transmission ) in intermediate prevalent regions like India.  
Age distribution  
Table 6 :  showing age distribution 
Age in yrs <18 18-40 >40 Total  
No .s 14 (8.75%) 93(58.12%) 53(33.1%) 160 
 
86
74
male
female
Figure 6 : Bar diagram showing age distribution 
 
 Hepatitis B infection can occur at any age group. In my study, 8.75% were in the age 
group less than 18 years , 58%  were  in the age group of 18-40 years and 33% (53/160) 
were above 40 years, of which 11(53) were above 60 years of age group . This shows that 
young adults are most common affected age group, indicating that infection has occurred 
either in infancy or childhood. This can be explained  by the intermediate prevalent 
region. 
Stage wise distribution of CHB: 
Table 7 : showing various stages of CHB 
 
Staging Inactive CHB Active CHB Cirrhosis Total  
No.s 134(83.75%) 19(11.87%) 7(4.37%) 160 
 
0
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14/160
93/160
53/160
No.s
Figure 7 : Bar diagram showing  Phasic distribution of CHB 
      
. 
Among chronic hepatitis B infection, 83.75% were in inactive chronic hepatitis B 
phase(asymptomatic carriers).11.87% were in active chronic hepatitis B phase and 4.37% 
are cirrhotics. Our study found that asymptomatic carrier state is the commonest mode of 
presentation followed by active chronic hepatitis infection and the least is cirrhosis of 
liver. Hence this study correlates well with the available literature.  
 
 
Correlation of qHBsAg levels with HBV DNA levels: 
 
Correlation between HBeAg positive & HBeAg negative group 
 
Table   8 : showing qHBsAg & DNA levels in e-antigen positive and e-negative groups 
0
20
40
60
80
100
120
140
Inactive CHB Active CHB cirrhosis
134
19
7
                  
 
  
 . 
 
 
 
 
 
 
   In our study we 
found, serum 
HBsAg  levels 
are higher in 
HBeAg  positive 
group than HBeAg negative group with a mean of 4.25logIU/ml and 2.81logIU/ml 
respectively. Also HBsAg levels significantly correlates with  HBVDNA levels in 
HBeAg  positive group with a  P value of <0.001.  But serum qHbsAg levels did 
not show significant correlation with HBV DNA levels in HBeAg negative 
patients.  
 HBV DNA 
(logIU/ml)  
qHBsAg  
(logIU/ml)  
P value  
HBeAg 
positive  
6.51  4.25  <0.001  
HBeAg 
negative  
2.5  2.81  0.147  
                                      
                                     The similar  observations were also seen in other studies . A 
study   by Jeyamani et al 
57
  found that   serum HBsAg levels  were higher in 
HBeAg positive patients  with a mean of 4.52logIU/ml and  significantly correlated 
well with DNA levels but in HBeAg negative group ,the  serum HbsAg levels  
were lower with a mean 3.2logIU/ml and did not correlate with HBV DNA levels. 
A study by Jaroszewicz also found the similar results with higher HBsAg levels in 
HBeAg positive group than in HBeAg negative group
7
. 
                       
 
 
 
 
 
 
 
 
Subgroup  analysis  in HBeAg  positive group.  
                              
                                    It is difficult to differentiate between immune-tolerance and 
immune-clearance  phase with ALT & HBV DNA levels. But serum HBsAg levels 
were higher  in immune tolerant phase than in  immune-clearance phase which was 
observed in a study by Jaymani et al 
57
.  
The following table shows the analysis of qHBsAg levels in these two groups in 
our study. 
 
Table  9 : qHBsAg and DNA  levels in Immune -tolerant & Immune-clearance 
patients                          
                     
 
 
 
 
 
 
 
 
We observed that serum HBV DNA levels  and ALT levels did not show 
significant difference among immune-tolerant   and immune-clearance phase. So 
 Immunetolerant  
 
Immuneclearance  
 
P value 
ALT  25 (19-36) 76 (42-204) 0.61 
DNA (logIU/ml) 6.79 6.08 0.79 
qHBsAg(logIU/ml) 4.59 3.73 0.038 
these variables cannot differentiate immune-tolerant  from immune-clearance 
phase (P= NS), where as  serum qHBsAg  levels  were higher in immune-tolerant 
phase than immune-clearance phase with mean  value of  4.59logIU/ml in immune-
tolerant  phase and 3.74logIU/ml in immune-clearance phase.  So qHBsAg  levels 
can   differentiates the two phases with a significant  P value of  0.038.  
 
                                              Two cross-sectional studies from Europe and Asia 
also found the higher serum HBsAg levels in  immune-tolerant phase with a  mean 
value of 4.96logIU/ml in immune tolerant and 4.37 logIU/ml in immune-clearance 
phase
27
. Our study correlates with the other studies.  
 
 
 
 
 
 
 
 
 
qHBsAg levels in Inactive carriers Vs Active CHB: 
 Table  10 : showing qHBsAg  levels in inactive & Active CHB 
  
                     
    
 
 
 
                                   Serum HbsAg levels are higher in active chronic hepatitis B 
group than inactive carriers with a values of 4.20logIU/ml and 2.64logIU/ml 
respectively ( P=0.002). Hence   higher values indicates active disease .  
 
                               The same observations were found in another Indian study by 
Jeyamani et al, stating that higher values are seen in active CHB than inactive 
carriers
57
.  
 
 
 
 
Diagnostic utility of  qHBsAg  in HbeAg  positivity: 
 Inactive carrier 
(DNA<2000Iu/ml)  
Active infection 
(DNA>2000IU/ml)  
P value  
qHBsAg  2.64  4.20  0.02  
 When Reciever Operating characteristics Curve( ROC)  was drawn to predict the  
status of HBeAg positivity by serum HBsAg levels, the area under the curve is 
0.82 with a significant P value of <0.001 ( 95% confidence interval  is 0.73 – 0.92). 
The curve follows as. 
 
                         Figure 7 : ROC curve depicting qHBsAg in HBeAg positive state 
 
 
  
 
From the above ROC curve,  serum HBsAg level of 3.01logIU/ml  indicates high 
chances of replicative state with 96% sensitivity and 76% specificty.  
Where as HBeAg negative ROC curve showed low diagnostic utility. Diagnostic 
utility of  HBsAg levels in HBeAg positive group showed positive results in other 
studies using ROC curve by Jeyamani et al 
57
.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CORRELATION OF qHBSAG LEVELS IN  THE TREATMENT GROUP : 
                                           
                                          Among 160 patients only 24  were included in treatment 
group . All  24 were treated with Nucleotide analogues( Tenofovir). Post treatment 
HbsAg levels and DNA levels are monitored every 12 weeks.  
Follow up period was 36 weeks with the treatment.  
There results are as follows. 
 
HBeAg positive group : 
 
Table 11  : correlation of  qHBsAg levels with DNA 
 
Variables Baseline  
(logIU/ml) 
12 weeks 
(logIU/ml) 
36 weeks 
(logIU/ml) 
P value 
qHBsAg 4.49(3.8-5.0) 4.35 4.13(3.0-4.8) NS 
DNA 6.97(3.5-8.0) 4.59 4.08(2.8-4.9) 0.002 
 
 
With the NUC‘s therapy the decrease  in qHBsAg  levels are very slow and 
showed  less than  1log drop at 12 weeks  from baseline,  the response at 36 weeks  
also did not show significant reduction in serum HBsAg  levels(P=NS). On the 
other hand DNA levels showed >1log  drop from baseline and had good response 
at 36 weeks(P=0.002).  
                                   The data from  the studies by Cai et al, Jaroszewicz et al, 
borgniet et al.   suggests that HBsAg reduction with NUS‘s are slow and less 
pronounced than interferon treatment, despite significant drop in  HBV DNA 
levels
52-54
. Our  study also supports the existing data. 
 
 
 
 
 
 
 
 
 
 
 
 
HBeAg  negative group : 
 Table 12  : correlation of  qHBsAg  with DNA levels 
 
Variables Baseline 
(logIU/ml) 
12 weeks 
(logIU/ml) 
36 weeks 
(logIU/ml) 
P value 
qHBsAg 3.87(2.5-4.98) 3.69 3.03 o.87 
DNA 5.56(3.7-8.0) 5.06 3.56(0.7-4.0) 0.001 
 
 
                                            In HBeAg negative group, decline  in serum HBsAg 
levels follow the same pattern as in HBeAg positive group i.e slower rate without 
significant decline at 36 weeks.  Though the HBVDNA   decline is also slow in 
HBeAg negative group compared to HBeAg  positive group, but  there is 
significant reduction (P=0.001) at 36 weeks when compared to HBsAg  levels .  
Hence serum HBsAg levels does not go in parallel with DNA levels.  
                                               The results in our study are similar to other studies by 
Jaroszewicz et al 
52
 and Cai et al
53
.  
 
 
Table  13 : CHB patients with undetectable DNA but detectable qHBsAg 
     
                
Variables qHbsAg ( n=160) DNA (n=160) 
No .s 18 0 
 
                           
                        Figure 8: Bar diagram showing % of qHBsAg  in undetectable DNA 
 
                                             Among 160 patients in our study, undetectable DNA 
levels found in 18(11.3%)  patients but serum HBsAg levels were detected in these 
18 patients. In those  15/18 were in inactive carrier stage, 2/18 were in active 
chronic hepatitis B and 1/18 in cirrhotic group. The latter two groups were on 
NUC‘s therapy.  
                                          This indicates that serum HBsAg levels take a longer 
course to become undetectable  after the elimination of DNA levels  from serum. 
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As supported by Borgniet et al, the average time taken for  HBsAg loss after 
undetectable HBV DNA was around 30 months 
54
.  
                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             DISCUSSION  
 
                                        HBsAg levels reflects the true cccDNA levels rather than 
serum HBV DNA levels. Hence  HbsAg quantification (qHBsAg)  can serve as a  
biomarker for prognosis and the treatment response in CHB. Though its 
importance was recognized in the past, its usefullness and interest  has captured the  
Hepatologist  recently. The reason being is it has shown strong positive correlation 
with intrahepatic cccDNA levels, so it has a  ability to predict spontaneous HBsAg 
clearance and e-antigen seroconversion on antiviral therapy
58
. The other important  
applications of qHBsAg levels are , low levels at baseline predicts interferon 
induced HBeAg serocnversion and ability to stratify the risk for the development 
of Hepatocellular carcinoma(HCC) in CHB. A study by Lin et el. have shown that 
qHBsAg>1000IU/ml & DNA<2000IU/ml is associated with high risk of HCC
59
. 
                                      
                                          Ours  is a prospective study done to evaluate the role of 
qHBsAg levels in comparing with HBV DNA levels  in the natural course of 
treatment naïve  CHB infection . Our study also  monitored  the qHBsAg levels in 
patients on  NUC‘s to look for the response in predicting the sustained response in 
compared with HBV DNA levels.  
 
Clinical characteristics : 
                             Our study showed no sex predeliction and the common age of 
presentation was between 18-40years , which correlate with the available data. 
Among 160 patients, majority were in inactive carrier state ( 83.75%). The rest 
being active CHB (11.87% ) and cirrhosis of liver in 4.37%. The commonest 
presentation in our study is asymptomatic i.e incidentally detected on regular 
master  check up or screening of blood donors.  
 
HBsAg kinetics in treatment naïve CHB:  
                                        
                                On evaluating qHBsAg levels in CHB patients, we found that 
qHBsAg  levels were higher in HBeAg positive group with a median value of 
4.25logIU/ml. This correlate significantly with DNA levels (P = <0.001).  
These findings are consistent with studies by Jayamani et al
57
 and other Asian & 
European countries 
24,28
. These studies also found higher and significant qHBsAg 
in HbeAg positive patients.  
                                 
                                
                                              On the otherhand  qHBsAg levels are much  lower in 
HBeAg negative patients with a median of 2.8logIU/ml and does not correlate with 
DNA levels unlike HBeAg positive . An Italian  study by Brunneto et al
28
 found 
the similar results.  
 
                               A subgroup analysis was done to differentiate between inactive 
chronic hepatits B infection from active chronic hepatitis B. This study found that 
the serum qHBsAg levels are higher in active chronic hepatitis B patients  with a 
median of 4.20logIU/ml when compared to inactive chronic hepatitis B patients  
with a median value of 2.64logIU/ml, which is statistically significant (P=0.002). 
Hence the higher value clearly differentiates inactive CHB from active CHB 
patients.  
 
                              A longitudinal study from Hongkong also found that higher 
qHbsAg levels in active disease and   significatnly differentiates between active 
and inactive CHB with a median values of 2.98logIU/ml vs 2.24logIU/ml  (P = 
0.05) respectively
24
. Another Itlalian study  by Brunetto et al found that serum 
HBsAg levels are significatly lower in inactive CHB than active CHB
28
. 
                                    
                                  
                                                In CHB , it is difficult to differentiate 
immunotolerant phase from immunoclarence phase with ALT & DNA levels as 
these levels will be fluctuating throught the course. Though the American and 
European guidelines uses DNA cut off of 2000IU/ml to differentiate the two , 
controversy still exists in many countries.  Hence we studied the role of qHBsAg 
levels in differentiating immunotolerant from immunoclearance phase. We found 
that serum qHBsAg levels were significantly higher inimmunotolerant phase with 
a median of 4.59logIU/ml when compared to immunoclearance phase with a 
median of 3.73logIU/ml (p = 0.038).  
 
                            Studies from Europe and Hongkong also found a similar results 
of  higher values in immunotolerant phase than immunoclearnace phase with a 
median of 5logIU/ml and 4.9logIUml respectively
5
. These studies also  concluded 
that serum   qHBsAg  value of more than100000IU/ml  significantly differentiated 
between immune-tolerant and immune-clearance phase. But we did not find the 
particular single value in differentiating the two.  
 
                                We also found that single point estimation of serum qHBsAg 
using ROC curve with a  value of 3.1logIU/ml indicates high chances of  
predicting replicative state with  96% senstivity and 76% specificity. Our study is 
supported  by another indian study by Jeyamani et al which also showed the 
similar results
57
. 
 qHBsAg  kinetics with NUC‘s:  
                                     
                                    Data suggests that fall in serum qHBsAg levels are slower 
and less pronounced with NUC‘s when compared to Interferon therapy. Serum 
qHBsAg fall does not fall in  parallel  with DNA levels with NUC‘s.  
 
                                    Our study showed decline in qHBsAg levels with  NUC‘s 
but the rate of fall is slower when compared to DNA levels among both HBeAg 
positive and HBeAg negative patients. At 12 weeks with NUC‘s therapy , DNA 
levels showed >1logIU/ml reduction from the baseline but serum qHBsAg levels 
showed <1logIU/ml reduction from baseline. So serum qHBsAg levels did not 
correlate well with DNA levels on patients with NUC‘ therapy.  
 
                                  Brunetto et al.  and Chan et al. found that drop in serum 
qHBsAg levels of more than 1logIU/ml from baseline would predict the HbsAg 
seroclearance on follow up of  34± 23 months. Also found that fall in HbsAg level 
can predict the stopping the therapy 
41,55
.  But our study followed only for  
36 weeks, hence prediction of  sustained response was not able to conclude based 
on the available data.  
                              We also found that in around 11.25% (18/160) serum qHBsAg 
levels were detected despite undetectable DNA levels. The reason being qHBsAg 
levels takes long time to disappear from serum. Same findings were also observed 
in another study by Borgniet et al
54
. This indicates that serum qHBsAg levels 
might be better marker in predicting seroclearance and can  guide in stopping the 
therapy. Further studies with longer duration are needed to conclude.  
 
 
 
 
 
                                          
 
 
 
 
 
 
 
 
                                               CONCLUSION 
1. High serum qHBsAg levels has a good correlation with HBV DNA levels 
in HBeAg positive than HBeAg negative patients.  
2. Hence single point estimation of qHBsAg levels can predict replicative 
state and can act as a surrogate marker for the replicative state.  
3. Higher qHBsAg levels also differentiates inactive CHB from active CHB 
and can replace  HBV DNA levels in differentiatin the two. Estimation of 
qHBsAg is easy and cost effective.  
4. Serum qHBsAg levels decline slowly  with NUC‘s  than DNA levels and  
decrease in serum qHBsAg levels  does not correlate with  decrease in 
HBV DNA levels.  
 
 
 
 
 
 
 
                               
 
                                            LIMITATIONS 
 
1. Single centre study 
2. Genotype assesment and qHbsAg kinetics based on genotypes were not 
assessed 
3. Treatment was followed only for short duration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             SUGGESTIONS 
 
1. Need multicentre study 
2. qHBsAg kinetics based on genotypes 
3. Longer duration of follow up  
4. Standardising the partcicular cutt-off of qHbsAg levels for stopping 
rule during therapy. 
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Role of serum HBsAg quantification in treatment of chronic 
hepatitis B infection. 
Proforma 
Name :                                               Age/Sex:                  IP No: 
 
Complaints : 
Past history: 
Family history : 
Personal history :  alcohol :    smoking: 
Others : 
 
Examination : 
GPE:   pallor/icterus/cyanosis/clubbing/edema/lymphnodes 
Pulse :                                    B.P 
Abdomen : 
R.S:                                                       CVS:                                  
CNS: 
Investigations : 
Hb%:             TC:                                    ESR:                        Plt: 
 LFT: TB:            DB/IB:                           OT/PT:         SAP:                   
Protein/albumin/globulin: 
RBS :                      FBS/PPBS:                            
PT/INR:  
Blood urea:                                 S.Creatinine: 
HBsAg:               HBeAg/antiHBeAg: 
IgMantiHBc: 
 Baseline 6 mnths 12mnths 
qHBsAg    
HBV-DNA    
Anti HCV:                                                       HIV: 
USG abdomen:                                             Chest X-ray: 
OGD : 
CTP Score:                                          MELD : 
Diagnosis : 
Ac.Hepatitis CHB Compen.CLD DCLD 
 
Antiviral drugs:   
       name :                         duration 
 
   
S.No Age Sex DDHD NO                                                             liver function test                                                HBeAg DNA(IU/L) QHBsAg    (IU/L)                     USG ABDOMEN LIVER BIOPSY       OGD FIBROSCAN          
bilirubin SGOT SGPT PROTEIN ALBUMIN GLOBULIN
1 33 M 1204/14 1 32 18 7.1 4 3.1 negative 3330000 12374.5 normal
2 33 F 0.8 24 22 6.9 3.9 3 negative 306/940 4540.14/17354.74 normal
3 52 F 1.4 41 28 7.4 4.4 3 negative 9.62 4197.72 fatty liver
4 49 F 1 20 19 6.8 3.6 3.2 negative 153 2756.62 normal
5 25 F 0.9 30 20 6.9 4.1 2.8 negative 43.9/<6                          5237.33/10510.83 normal
6 31 f 1.1 33 23 7.3 4.3 3 negative 2000 11359.04 normal
7 57 M 0.7 46 38 7.4 5.4 2 negative 196 10779.94 fatty liver
8 37 F 1.6 50 36 7.6 4.4 3.2 negative 361 6792.46 normal
9 2 M 31/14 0.7 54 50 7.2 3.8 3.14 reactive >110,000000                                             >100000 normal
10 45 F 322/14 0.37 27 25 6.8 3.7 3.1 negative <6 978.64 normal
11 27 F 1.2 22 32 7.2 4.2 3 negative 6.18 18675.8 normal
12 35 M 1.6 56 48 7.9 3.6 4.3 negative 1.83 2583.43 normal
13 22 F 1.1 54 90 7.2 4.2 3 reactive >110,000000/80,600 71116.85/63078.93 normal
14 48 F 1 22 30 7 4.1 2.9 negative 363 19435.73 fatty liver
15 58 M 1.2 33 30 6.4 3.8 2.4 negative 1250 1323.78 fatty liver
16 22 M 0.8 42 38 6.8 4 2.8 negative 16.3 20796.59 normal
17 38 M 5114/13 0.6 15 19 7 4.7 2.3 negative 124,000 2308.7 normal
18 32 M 1.2 22 32 7.2 4.2 3 negative 39.8 5276 normal
19 23 M 227/14 1.2 27 14 7.4 3.6 3.8 negative 902 2371.77 normal
20 34 M 213/14 1.6 56 38 7.6 4.4 3.2 reactive 3,81,00 33961.75 fatty liver
21 23 M 0.5 27 25 7 4 negative 6.66 1672.93 normal
22 33 F 136/14 1.2 27 14 7.4 3.6 2.8 negative 563 1444.62 normal
23 72 F 1.1 58 72 7.2 4.3 3 reactive 19,700,000 5657.79 fatty liver
24 50 F 1169/14 0.7 108 83 7.4 2 5.4 reactive >110000000/1060000/145 7712.74/939.82 normal
25 54 M 0.65 24 20 7 4 negative  undetected 939.82 normal
26 21 M 2 46 21 7.2 4.8 reactive >1100000001 <11791.82 fatty liver
27 28 M 0.55 27 25 6.8 negative 361 9137-57 fatty liver
28 18 M 206/13 1 25 37 8 4.2 3.8 negative 48000000 15341.81 normal
29 32 M 1 158 83 7.6 4 2.6 reactive 4329 18317.08 normal
30 43 M 0006/14 1.6 23 91 8.1 5.1 3 negative 5030 121.78 cld
31 37 F 1 19 22 7.7 4.7 negative nill 0.03 normal
32 63 M 2066/14 0.9 91 62 6 2.5 3.5 negative 81,300 2062.28 cld
33 21 F 573/14 1.1 44 31 7.2 4.1 3.1 negative 1850 7625.83 fatty liver 5.7pka
34 18 M 017/06/14 2.3 46 21 7.2 4.5 2.7 reactive >110000000,4640 22769.70, 33043.4 normal chronic active hapatitis
35 12 F 343/14 1 26 12 6.7 4.3 2.4 reactive 42700, undetected 4433.84,3079.31 normal
36 51 M 014/7/14 0.9 42 28 6.6 3.8 2.8 negative 40.1 1870.55 normal
37 69 M 3113/14 1 24 22 6 3.5 2.5 negative 559 414.9 normal
38 23 M 1197/14 0.7 19 26 6.8 3.8 3 negative 551 19112.24 normal
39 29 M 2121/14 0.95 21 38 7.2 4.5 2.7 negative 687 75.75 normal
40 65 M 1 32 30 6 4 2 negative 8.89 64.11 normal
41 39 M 1.3 34 30 6.7 4.3 2.4 negative 87.9 2051.8 normal
42 64 M 3960/12 1.6 128 138 7.6 3.6 4 reactive 15,000000, 1040 66000, 1385.77 CLD GIIVx
43 24 M 1.2 27 25 6 3.5 2.5 negative 14.5 1081.7 normal
44 42 M 1.1 34 28 6.4 4.4 2 negative 1140 2996.78 normal
45 17 F 1.8 46 44 7.2 4.5 2.7 reactive 27000000 27000 normal
46 42 M 0.8 50 41 6.8 4.4 2.4 negative 736 4751.55 normal
47 36 F 1 32 30 7.1 4.1 3 negative undetected 1632.61 normal
48 39 M 0.85 26 34 7.2 3.8 3.4 negative 1650 1167.92 normal
49 48 M 615/12 1.8 50 23 8.1 3.6 4.5 negative 95.5 367.77 CLD
50 22 F 6101/12 0.9 42 24 7.1 4.6 3 negative <6 1130.77 normal
51 27 F 017/7/14 4.3 42 24 7.6 2.9 4.2 negative <6 189.9 CLD
52 27 F 1177/09 0.9 42 28 5 2 3 negative 560 21780.62 CLD
53 67 M 168/14 0.9 26 34 7.2 3.8 3.4 negative undetected 0.02 normal
54 43 M 1.1 26 24 6.7 4.5 2.2 negative 649 1282.59 normal
55 20 F 1.2 48 54 6.9 3.6 3.3 negative 70.7 11635 fatty liver
56 24 F 1.5 52 42 6.8 4.4 2.4 negative 833000 1588.25 fatty liver
57 51 F 0.8 32 22 6.6 4.6 2.4 negative undetected 1.83 normal
58 19 F 0.65 19 21 7 4.1 2.9 negative <6.0 538.64 normal
59 27 F 0.5 22 18 6.9 3.9 3 negative 202 0.03 normal
60 49 M 1 32 24 6 3.5 2.5 negative <6 1808.04 normal
61 15 M 7665/13 0.2 26 34 7.1 4.2 2.9 reactive >1100000, 131000 >100000, 100000 normal
62 6 F 7652/13 0.4 49 47 6.9 4.9 2 reactive 110000, 25700 >100000,  73492 normal
63 29 F 3594/13 0.8 52 34 7 4 3 negative 29.2 2765.9 normal
64 59 F 1.1 28 34 6.6 4.2 2.4 negative undetected 0.8 normal
65 29 M 1.2 47 42 7.2 3.7 3.5 negative 64.5 32657.22 normal mild hepatitis
66 53 M 1 60 44 6.8 4.8 2 negative >110000000 6706.75 fatty liver
67 29 M 934/14 1 34 25 8.2 4.8 3.4 negative 68.9 2315 normal
68 27 M 1500/10 2.1 30 24 7.7 4.5 3.2 reactive 111 14977.6 normal
69 65 M 1878/14 6.9 650 570 6 4.2 2.8 reactive 3730000 96719.9 fatty liver
70 34 M 2374/14 2.1 192 40 7.3 3.2 4.1 negative 99 3214 CLD
71 19 F 2561/14 0.7 27 20 7.1 4.6 2.5 negative 8.76 21165.07 normal
72 47 M 2559/14 0.6 23 17 6.8 4 2.8 negative 70100 3989 normal
73 42 M 2563/14 0.9 29 33 7 4 3 negative 5432 9762 fatty liver
74 31 F 2579/14 0.8 14 89 6.4 4.2 2.7 negative 1800 12413.73 normal
75 36 M 1 30 26 7.2 4.2 3 negative 42.3 1093 normal
76 34 F 2615/14 1.2 38 40 6.9 4 2.9 negative 3220 3109.21 normal
77 14 M 2386 0.5 48 30 7.4 4.4 3.4 reactive >110000000 1000000 fatty liver
78 26 F 2087/14 0.4 48 34 6.6 3.6 2 negative 541 3000 normal
79 24 F 2649/14 0.9 33 23 7.7 4.5 3.2 negative 6.9 3608.26 normal
80 50 F 4174/12 1.6 52 29 7.7 3.5 4.2 negative 108 1207 normal
81 33 F 2385/14 0.3 32 36 6.9 4.6 2.3 negative 319 23264 normal
82 39 F 2227/14 0.5 52 54 6.4 3.2 3.2 negative 109 1631 fatty liver
83 35 M 1.1 41 38 6.4 4.2 2.2 reactive 529 1499.78 fatty liver
84 37 M 1520/14 0.9 37 35 7.9 5.3 2.6 negative <6 273.22 fatty liver
85 33 M 1.6 36 29 7.2 4 3.2 negative 224 52458 fatty liver
86 25 F 1.1 40 45 7 4.1 2.9 negative <6 3135 normal
87 27 F 2223/14 0.46 21 16 6.4 3.4 3 negative 184000 11255.59 normal
88 27 F 1914/14 0.9 39 33 6.9 3.9 3 negative undetected 141.69 normal
89 32 F 0.89 24 29 6.7 4.7 2 negative undetected 0.9 normal
90 72 M 1.2 31 29 6.4 3.2 3.2 negative <6 35.02 fatty liver
91 30 F 0.9 39 28 7.7 4.7 3 negative <6 2636.7 normal
92 15 M 1 21 19 6.2 3.6 2.6 reactive >110000000 100000 normal
93 18 F 2334/14 0.8 21 57 6.6 4 2.6 reactive >110000000 100000 normal
94 21 F 030/6/14 1 20 36 6.9 4 2.9 negative <6 1368.62 normal
95 33 M 6556/11 1.1 30 21 8 4.1 3.9 negative undetected 545.85 CLD GIVx
96 56 M 1674/11 1.5 30 21 7 4.7 3.3 negative 412 2265.3 CLD GIIVx
97 70 F 6213/12 1.6 42 40 6.2 4.1 2.1 negative 67 1834.9 fatty liver
98 37 M 3048/14 1.3 36 42 6.9 3.9 3 negative 2240 4121.11 normal
99 24 M 2975/14 6.9 165 43 7.9 4.2 3.7 negative 18.6 8162.09 normal
100 33 M 2550/14 1.9 23 22 7.3 4.3 3 negative 43 879.9 normal
101 49 F 2890/14 5 204 588 6.8 3.6 3.2 negative 94.7 196.33 normal
102 49 M 3219/11 0.6 40 41 6.9 4.4 2.5 negative 9.43 1851.94 normal
103 52 F 2766/14 0.9 19 16 8 4.2 3.8 negative 186 1650.18 normal
104 18 M 4066/13 2 24 25 7 4.2 2.8 negative 152 6284.92 normal
105 42 F 3638/14 1 22 2.6 7.4 4.4 3 negative <6 7749 fatty liver
106 55 M 2957/14 1.4 36 34 7.6 3.8 2.9 negative 238 547.11 normal
107 55 F 4010/13 1.1 36 48 6.9 4.2 2.7 negative undetected 570.39 normal
108 22 F 2947/14 1.1 25 19 7.8 4.7 3.1 negative <6 4886.76 normal
109 35 F 3865/14 0.89 39 40 6.5 3.5 3 negative 19.3 987.07 fatty liver
110 18 F 3608/14 1.3 30 25 7.3 4.1 3.2 negative undetected 281055.77 normal
111 23 F 3533/14 0.7 32 42 5.5 3.2 2.3 negative <6 21838.05 normal
112 44 M 1 41 38 6 3.8 2.2 negative undetected 572.11 normal
113 56 M 0.87 30 23 6.7 3.6 3.1 negative 120000 3913.07 fatty liver
114 26 F 0.92 29 39 7.2 4.2 3 negative <6 17281.13 fatty liver
115 66 M 1.2 35 40 6.9 3.9 3 reactive >110000000 32963.68 normal
116 25 M 1 29 39 7.8 4.9 2.9 negative 1620 7661.1 normal
117 33 M 0.86 30 41 6.9 4 2.9 negative undetected 0.32 normal
118 31 F 1.6 39 31 6.2 4 2.2 negative 116 2240.36 normal
119 40 F 1.3 36 29 6.7 3.9 2.8 negative 1990 1255.83 normal
120 49 M 0.92 40 36 7.6 4.6 3 negative 1720 442.05 normal
121 42 F 1.1 32 40 7.1 4.2 2.9 negative <6 817.2 normal
122 40 M 1.4 29 33 6.7 3.5 3.2 negative undetected 3934.71 normal
123 20 F 0.99 26 39 6.7 3.9 2.8 negative 2790 7815.05 normal
124 56 F 0.79 45 41 6.2 3 3.2 negative 806 3780.89 fatty liver
125 51 M 1.3 25 31 7 4.8 2.2 negative <6 439.84 normal
126 31 M 1.6 49 44 6.6 3.3 3.3 negative 2280 61850.8 fatty liver
127 54 M 3385/11 0.7 77 71 5.5 2.5 3 negative undetected 2033.57 CLD
128 39 M 6784/09 7.3 216 263 5.9 2.3 3.6 negative undetected 273.44 CLD GIVx
129 27 F 1 43 39 7.5 4.4 3.1 negative 189 16782.27 fatty liver
130 31 M 1.4 37 27 7.9 4.2 3.7 negative 1120 3077.99 normal
131 37 M 0.89 35 27 6.9 4 2.9 negative 2240 4121.11 normal
132 70 M 5722/12 1.4 24 32 5.2 2.2 3 negative <6 363.3 CLD
133 37 M 2977 2.4 115 86 6 3.2 3.4 reactive 131000 65300 CLD GIIVx
134 40 F 3755/14 0.5 33 44 7.2 4.5 2.7 negative 1555826 23400 normal
135 45 M 4294/14 0.78 26 31 7.4 4.4 3 negative 43.5 789.61 fatty liver
136 37 F 4480/14 1.1 32 28 8 4.8 3.2 negative <6 379.6 normal
137 48 F 4474/14 1.6 37 29 6.7 3.7 3 negative 32.3 769.54 normal
138 21 F 4059/14 0.7 33 27 7.4 4.1 3.3 negative 168 16166.8 normal
139 24 M 7627/13 1 65 88 8.9 4.9 4 reactive 1844.27 110000 fatty liver
140 28 M 4228/14 0.7 43 69 7.3 4.4 2.9 negative 2930 9589.65 normal
141 18 F 3608 1.3 30 25 7.3 4.1 3.2 negative undetected 281055.77 normal
142 50 M 7753/13 2.5 830 929 8.7 3 5 reactive 109000000, 110000000 9000, 13000 fatty liver
143 25 F 2606/14 0.7 30 23 6.7 4.5 2.2 reactive 110000000 20461 normal
144 24 F 4366/14 1 26 20 7.1 3.9 3.2 negative 6.13 2114.32 normal
145 23 F 7136/13 1 35 30 7 3.9 3.1 negative 9.89 7594.96 normal
146 22 M 4362/14 0.79 35 27 6.4 4.1 2.3 negative 246 6031.68 normal
147 23 M 4268/14 3.4 465 541 7.2 4.2 3 reactive >110000000 >100000 normal
148 25 F 0.7 21 27 6 3.5 2.5 negative <6 10510.83 normal
149 24 F 1.4 30 36 7.3 4.3 3 negative 1070 3443 normal
150 32 F 4323/14 1.3 28 19 6.1 3.2 2 negative 13100000 7805.17 normal
151 47 M 0.89 18 27 6.7 4 2.7 negative 761 1120.9 normal
152 46 M 1.4 37 26 8.1 4.9 3.2 reactive 5270000 4104.15 fatty liver
153 43 F 4613/14 0.7 29 27 6.6 4.6 2 negative 648 9705.25 fatty liver
154 31 M 4596/14 1.5 53 28 6.9 4.9 2 negative 16.4 4931.99 fatty liver
155 18 M 4879/14 9.6 1280 2430 7.2 4.3 2.9 reactive >110000000 100000 normal
156 30 F 4995/14 0.98 22 40 6.8 4 2.8 negative 45 1093.8 fatty liver
157 38 M 3011/13 1 19 31 5.4 3.4 2 negative <6 68.8 normal
158 40 M 6901/11 2.1 54 30 6.3 3.9 2.4 negative undetected 572.81 normal
159 55 F 4999/14 1.3 32 56 7.8 4.5 3.3 negative 415.3 1865.4 fatty liver
160 40 M 4933/14 0.54 29 29.2 6 3.7 2.3 negative 736 1009.42 normal
S.No Name Age/Sex Diagnosis CTP Score HBeAgqHBsAg     IU/ml                                                                  HBV DNA         IU/ml                             treatment    
baseline 12wks 24wks 36wks baseline 12wks 24wks 36wks
1 lokeshwari 22 Active CHB  NA positive 71116.89 66820 63078.75 59876 >1,10000000 52061.6 80,600 72389 tenofovir
2 satish 18 active CHB NA positive 15341.82 18317.08 11713.2 10823 48,000,000 UD UD tenofovir
3 gopal 3 active CHB NA positive >1,00,000 80,456.26 74658.8 71166 >110,000,000 63074.61 92624 80509 lamivudine
4 krbakaran 18 active CHB NA positive 27,400 16240 11251 96827 >110,000,000 92426 71426 82368 tenofovir
5 thulasimmal 12 active CHB NA positive 4433.84 4086.64 2893 42700 21800 30650 tenofovir
6 kalliammal 37 active CHB NA positive 6792 5640 3890 2658 3610 1800 876 658 tenofovir
7 saravan muthu 44 CLD CTP A negative 4231.23 2650 1685 86 5540 3580 2800 <6 telbuvidine
8 murugesh 27 CLD CTP A negative 6423.12 2982.82 1089.22 146 4640 223 62.34 UD telbuvidine
9 sandhya 6 active CHB NA positive >100,000 73492 59876 42768 110000 25700 16800 4700 lamivudine
10 suman 15 active CHB NA positive >100000 100000 89600 >1100000 131000 96700 telbuvidine
11 moses 47 DCLD CTP B negative 367.37 258.9 189.8 109.3 95.5 <6 UD UD telbuvidine
12 chokkanathan 27 active CHB NA negative 14977.6 10846 6839.7 3362.9 11189 6570 3200 867 telbuvidine
13 anbalagan 50 acute flare NA negative 9000 13650 8650 6670 >10000000 >110000000 189000 96500 telbuvidine
14 raje 65 active CHB NA negative 2062.28 987.67 589 268 81300 56400 19800 8870 telbuvidine
15 sarasu 50 CLD CTP A negative 14881.6 7712.16 2874.2 759.16 >110000000 1060000 76500 29800 telbuvidine
16 kothandan 51 CLD CTP A negative 4238.57 2033.57 1720.05 957.5 2539033 165000 54200 UD entacavir
17 sekar 47 active CHB NA negative 3989.19 1876.19 1099.9 658 701000 90500 8760 250 telbuvidine
18 chengalvarayan 61 CLD CTP A negative 36500 16230 1385 886 15100000 198000 1040 56.8 tenofovir
19 mani 34 active CHB NA negative 33961.75 28957.75 19860 11798 381000 297000 109000 87600 tenofovir
20 devasundaram 37 active CHB NA negative 3568.12 3090 2668.2 1969 131000 99700 50750 33500 tenofovir
21 manju 25 active CHB NA positive 20461 9892.6 4682 2279 110000000 108900 60460 11590 tenofovir
22 murugan 43 CLD CTP A negative 1211.78 782.22 178 5030 3800 1070 telbuvidine
23 munwar 24 active CHB NA positive 20165 9957.28 5749 1020 110000000 99700 10650 2370 telbuvidine
24 annalakshmi 27 active CHB NA negative 11255.5 8690.5 5909 2305.5 184,000 65200 11800 3350 tenofovir
25 ramesh 27 active CHB NA negative 4632.25 4079.2 3276 1976.25 7889 5980 3688 1690 tenofovir
26 venkatesh 40 active CHB NA negative 96500 52486 18600 10040 1,555,826 196500 100000 67800 tenofovir
